TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16736081
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of harm reduction and social norming messages
Study: 7761019
Drug: Betamethasone 0.1
Normalized name: betamethasone 0.122 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 0.1 mg/kg administered 10 min after continuous infusion of vecuronium
Study: 7761019
Drug: Vecuronium 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.08 mg/kg bolus followed by continuous infusion of 0.4‐0.5 micrograms/kg/min
Study: 3288070
Drug: Aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 500 mg tid for seven days
Study: 31965579
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 25 mg orally once daily
Study: 7955939
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg kg‐1)
Study: 23963274
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (2 mg/kg/day for 60 days)
Study: 21598858
Drug: Analogy-guided learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analogy-guided learning activities incorporated into weekly group discussions, reflective journal writing, and questioning with clinical faculty.
Study: 19090531
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) including Individualized Sleep Promotion Plan (ISPP) with modified stimulus control, modified sleep restriction, relaxation therapy, and sleep hygiene.
Study: 16720830
Drug: Hematide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematide 0.1 mg/kg
Study: 15464488
Drug: Papaverine injection
Normalized name: papaverine Injection
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine injection before harvest (Group 2)
Study: 11779325
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment and observation
Study: 9025770
Drug: 5-fluorouracil (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (375 mg/m2 per day) and leucovorin (200 mg/m2 per day) administered intravenously (days 1-5) with levamisole (30 to 470 mg/m2 per day) administered orally (days 1-3 and 15-17)
Study: 8513037
Drug: Late melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late melatonin (5 mg for 5 days after 3 days of placebo)
Study: 8513037
Drug: Early melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early melatonin (5 mg started 3 days prior to arrival until 5 days after return home)
Study: 23722592
Drug: Recombinant adenoviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenoviral human p53 gene therapy (rAd‐p53) with radiotherapy (60 Gy)
Study: 12938264
Drug: 5-FU-based chemotherapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU-based chemotherapy
Study: 12938264
Drug: 5-FU or
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU or other cytotoxic agent alone
Study: 8783704
Drug: Inappropriate antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate antimicrobial treatment
Study: 1385761
Drug: Toremifene 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 200 mg/m2 p.o. daily
Study: 1385761
Drug: Toremifene 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 300 mg/m2 p.o. daily
Study: 1385761
Drug: Toremifene 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene 400 mg/m2 p.o. daily
Study: 1385761
Drug: Toremifene (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (all doses)
Study: 1385761
Drug: Toremifene pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene pharmacokinetics
Study: 30663156
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise intervention (1-h weekly diet sessions and 75-min bi-weekly physical activity sessions)
Study: 29746725
Drug: DS-2969b (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-2969b (6 mg, 20 mg, 60 mg, 200 mg, 400 mg, 600 mg)
Study: 29746725
Drug: DS-2969b (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-2969b (60 mg or higher)
Study: 26881019
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary total polyphenol excretion (TPE)
Study: 25257875
Drug: Insulin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (5 mU·kg(‐1)·min(‐1))
Study: 15127089
Drug: Vegetable juice
Normalized name: Vegetable Juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable juice supplementation (one can daily)
Study: 15127089
Drug: Placebo (orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orange soda, placebo pill daily)
Study: 11779889
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 to 325 mg per day)
Study: 2062511
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg per day)
Study: 11779889
Drug: Aspirin (975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (975 to 1300 mg per day)
Study: 11779889
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (no antithrombotic drugs or ticlopidine)
Study: 9842977
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg x 2
Study: 9842977
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg x 2
Study: 9842977
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg with Niflumic acid (250 mg)
Study: 9842977
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg with Paracetamol (500 mg)
Study: 7734464
Drug: Matrix outpatient
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix outpatient stimulant treatment
Study: 2477936
Drug: Flutamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (750 mg/d)
Study: 31560137
Drug: Benazepril (0.5‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (0.5‐1.0 mg/kg) administered PO once daily for up to 2 years
Study: 31560137
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered PO once daily for up to 2 years
Study: 28599199
Drug: 1L normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1L normal saline (NS) administered as a rapid infusion over 30 min
Study: 28599199
Drug: 1L normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1L normal saline (NS) administered as a slow infusion over 120 min
Study: 25557740
Drug: Higher cumulative
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cumulative bortezomib dose (≥39 mg/m²)
Study: 25557740
Drug: Lower cumulative
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cumulative bortezomib dose (<39 mg/m²)
Study: 25557740
Drug: Higher cumulative
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher cumulative bortezomib dose (≥39 mg/m²) after landmark analysis
Study: 25557740
Drug: Lower cumulative
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cumulative bortezomib dose (<39 mg/m²) after landmark analysis
Study: 19863282
Drug: MDIS (metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDIS (metered dose inhaler with spacer device)
Study: 19863282
Drug: Standard nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nebulizer therapy
Study: 16923091
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin treatment (short-acting insulin 1 IU/kg/h with 30% glucose 1.5 ml/kg/h)
Study: 16923091
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin treatment and Control treatment
Study: 14579657
Drug: 0.05% oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% oxymetazoline nasal spray (2 sprays, 0.1 ml/spray) 3 times daily for 4 weeks
Study: 14579657
Drug: 0.05% oxymetazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% oxymetazoline nasal spray
Study: 27830923
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments (Control group)
Study: 18163056
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation therapy
Study: 9808685
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg once daily for 10 days) with 10 mg/kg tirilazad mesylate orally
Study: 9808685
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg once daily for 10 days) with 2 mg/kg tirilazad mesylate i.v.
Study: 7851350
Drug: Propofol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (continuous intravenous infusion starting dose 3 mg kg‐1 h‐1)
Study: 1096908
Drug: Etidocaine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine at 10 mg/min
Study: 1096908
Drug: Etidocaine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidocaine at 20 mg/min
Study: 1096908
Drug: Lignocaine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine at 20 mg/min
Study: 28535819
Drug: Ibuprofen (overt)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (overt)
Study: 28535819
Drug: Paracetamol (overt)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (overt)
Study: 16719026
Drug: Static positional
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static positional stretches of the stroke‐affected shoulder twice daily and positioned the stroke‐affected upper limb in an armrest support at all other times when seated.
Study: 16719026
Drug: Treatment group.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group.
Study: 15232326
Drug: Olanzapine (OLZ)
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine (OLZ) 5 to 20 mg/d
Study: 15232326
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination (OFC) 5 to 20 mg/d olanzapine + 20 to 80 mg/d fluoxetine
Study: 11547961
Drug: Steroid-containing drug
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-containing drug delivery system (DDS)
Study: 11547961
Drug: Topical chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chloramphenicol eyedrops
Study: 8335134
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of zinc supplementation during pregnancy
Study: 24797300
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) with chemotherapy (idarubicin, cytarabine, and all-trans retinoic acid)
Study: 16845131
Drug: L-IVRA group
Normalized name: Ivra
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-IVRA group (lidocaine 0.5% with lornoxicam)
Study: 16845131
Drug: L-IV group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-IV group (intravenous lornoxicam and IVRA lidocaine 0.5%)
Study: 1928686
Drug: Propofol (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.6 mg/kg to 2.6 mg/kg in 0.2 mg/kg increments)
Study: 1928686
Drug: Propofol mixed
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol mixed with lignocaine (0.5 mg/ml)
Study: 30932955
Drug: MGN1703 (TLR9
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGN1703 (TLR9 agonist); 60 mg × 2 weekly for 24 weeks
Study: 23138399
Drug: Milrinone (MR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (MR; 0.5‐1 μg/kg/min)
Study: 23138399
Drug: Levosimendan (LEVO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (LEVO; 0.1‐0.2 μg/kg/min)
Study: 19637474
Drug: Extraction of
Normalized name: tree of heaven pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction of two maxillary first premolars and two mandibular first molars with additional micro-implants for orthodontic anchorage
Study: 16843643
Drug: Fexofenadine and
Normalized name: Fexofenadine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine and emollient treatment (Group 1) for 1 week
Study: 16843643
Drug: Fexofenadine and
Normalized name: Fexofenadine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine and steroid treatment (Group 2) for 1 week
Study: 29481430
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and oxycodone
Study: 27077832
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin solution between 8 and 12 hours post burn (n = 23)
Study: 27077832
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 5% albumin solution 24 hours post burn (n = 23)
Study: 22522549
Drug: BQ-123 (ETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (ETA receptor antagonist) at 400 nmol/minute for 60 minutes
Study: 22522549
Drug: BQ-123 (ETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (ETA receptor antagonist)
Study: 17827142
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day antibiotic therapy
Study: 17827142
Drug: 8 day
Normalized name: Jasmiel 28 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 day antibiotic therapy
Study: 11172215
Drug: Sucralfate administered
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate administered every 6 hours for 15 days (group A)
Study: 11172215
Drug: Water for
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for injection with strawberry flavor as placebo (group B)
Study: 3173616
Drug: CA.RP (keto-analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA.RP (keto-analogs with low protein diet 0.4 g/kg/day)
Study: 3173616
Drug: CA.RN (keto-analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA.RN (keto-analogs with normal protein diet 1 g/kg/day)
Study: 25471002
Drug: Antiviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral agents
Study: 25471002
Drug: TENS and
Normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS and Antiviral agents
Study: 12612223
Drug: Intratracheal r‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline) every 48 hours for up to 1 month
Study: 12612223
Drug: Intratracheal r‐h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal r‐h CuZnSOD (5 mg/kg in 2 mL/kg saline)
Study: 10805052
Drug: Candesartan cilexetil/hydrochlorothiazide
Normalized name: Candesartan Cilexetil/Hydrochlorothiazide 32 MG-25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil/hydrochlorothiazide 8/12.5 mg once daily
Study: 10805052
Drug: Lisinopril/hydrochlorothiazide 10/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/hydrochlorothiazide 10/12.5 mg once daily
Study: 6441624
Drug: Estrogen and
Normalized name: Conjugated estrogen and norgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen and calcium treatment
Study: 31754080
Drug: Mixed flavonoid
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed flavonoid supplementation (678 mg total, including 200 mg quercetin, 368 mg green tea catechins, 128 mg anthocyanins)
Study: 29098555
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin, etoposide, and irinotecan
Study: 22697628
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (implants surrounded by bone, no GBR)
Study: 12660500
Drug: Rapamycin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin 2 mg/day
Study: 10589950
Drug: Sirolimus (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1 or 3 mg/m2/day) with full‐dose CsA
Study: 10589950
Drug: Sirolimus (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (1, 3, or 5 mg/m2/day) with reduced‐dose CsA
Study: 10589950
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo with full‐dose CsA)
Study: 10589950
Drug: Sirolimus (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (3 mg/m2/day) with full‐dose CsA
Study: 10589950
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with CsA and steroids
Study: 8929747
Drug: Diltiazem 30
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 30 mg 3 times daily
Study: 8929747
Drug: Warfarin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 25 mg oral dose
Study: 6355792
Drug: Cimetidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.0 g/day)
Study: 6732224
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% acyclovir in polyethylene glycol ointment
Study: 21235040
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (up to 10 sessions, average of 8.6 sessions per patient)
Study: 12588269
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned Gp IIb/IIIa inhibition (n = 3011)
Study: 12588269
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus planned Gp IIb/IIIa inhibition
Study: 9546934
Drug: Heparin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin administration via nomogram (Group I)
Study: 9546934
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing scheme (Group II)
Study: 9546934
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing scheme (Group III)
Study: 1866869
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg p.o.
Study: 1866869
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg IV
Study: 6337697
Drug: DES 1
Normalized name: SENNOSIDES 15MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES 1 mg orally three times daily or orchiectomy
Study: 6337697
Drug: DES plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES plus cyclophosphamide at 1 mg/m2 iv every three weeks
Study: 6337697
Drug: Estracyt plus
Normalized name: Estracyt
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estracyt plus cyclophosphamide at 1 g/m2 iv every three weeks
Study: 6337697
Drug: Chemotherapy (DES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (DES plus cyclophosphamide or Estracyt plus cyclophosphamide)
Study: 12969694
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy alone
Study: 29045520
Drug: Cabozantinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (140 mg/day) in RET M918T-positive tumors
Study: 29045520
Drug: Cabozantinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (140 mg/day) in RET M918T-negative tumors
Study: 25271811
Drug: Fixed-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5)
Study: 25271811
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5)
Study: 24298783
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture with basic treatment (psychological counseling and Chinese patent medicine Rupixiao)
Study: 24298783
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with basic treatment only
Study: 22292367
Drug: Kudiezi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudiezi injection plus traditional Chinese medicine (TCM) synthesis rehabilitation project
Study: 19332202
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) and stenting with optimal medical therapy (1,101 patients)
Study: 19332202
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (1,100 patients)
Study: 19332202
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy in non-LAD group
Study: 9470078
Drug: Volume group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume group received a rapid (10‐min) 6 ml/kg infusion of a 6% hydroxyethyl starch preparation during mechanical ventilation (MV).
Study: 7887106
Drug: HF+TEA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF+TEA group (high-dose fentanyl + TEA with 10 ml bupivacaine 5 mg.ml‐1 followed by 4 ml every hour)
Study: 7887106
Drug: LF+TEA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF+TEA group (low-dose fentanyl + TEA)
Study: 7887106
Drug: HF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HF group (high-dose fentanyl 55 micrograms.kg‐1)
Study: 2974978
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route
Study: 2974978
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg dose of synthetic human calcitonin administered 6-hourly by intravenous route